Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.32 |
| ▸ | DRD3 | P35462 | 3/20 | 0.32 |
| ▸ | HRH1 | P35367 | 2/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | HRH2 | P25021 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5679108 | 1.00 | CYP2C9 (0.48) | CYP2C9LMNACHRM1CHRM3CHRM2 | |
| SCHEMBL6618128 | 1.00 | CYP2C9 (0.48) | CYP2C9LMNACHRM1CHRM3CHRM2 | |
| SCHEMBL14536225 | 1.00 | CYP2C9 (0.48) | CYP2C9LMNACHRM1CHRM3CHRM2 | |
| SCHEMBL6615911 | 0.91 | MAPK1 (0.40) | CYP2C9LMNACHRM1CHRM3CHRM2 | |
| SCHEMBL6616075 | 0.91 | MAPK1 (0.40) | CYP2C9LMNACHRM1CHRM3CHRM2 | |
| SCHEMBL7228894 | 0.79 | KDM4E (0.31) | — | |
| SCHEMBL7228899 | 0.79 | KDM4E (0.31) | — | |
| SCHEMBL7690956 | 0.79 | HTR3A (0.33) | — | |
| SCHEMBL11093871 | 0.76 | — | — | |
| SCHEMBL6575595 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197874-B1 | PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2016-08-31 | — | — | EP | disclosed |
| US-20160050929-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT PESTS | SYNGENTA LIMITED (GB) | 2016-02-25 | — | — | US | disclosed |
| US-20160046620-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT PESTS | SYNGENTA LIMITED (GB) | 2016-02-18 | — | — | US | disclosed |
| WO-2014154486-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT PESTS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-02 | — | — | WO | disclosed |
| US-8367658-B2 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-02-05 | — | — | US | disclosed |
| US-20120040967-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-8058045-B2 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-11-15 | — | — | US | disclosed |
| US-20100311730-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040967-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CHEK1, CHEK2, PLK1 | CYP2C9 4523/4885LMNA 773/4885CHRM1 3729/4885 |
| US-20100311730-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CHEK1, CHEK2, BUB1B | CYP2C9 4169/4885LMNA 621/4885CHRM1 2891/4885 |
| US-20160046620-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT PESTS | CRY1, DDT, CYC1 | CYP2C9 1123/4885LMNA 1870/4885CHRM1 139/4885 |
| US-20160050929-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT PESTS | DDT, CRY1, NISCH | CYP2C9 943/4885LMNA 1992/4885CHRM1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.